MET and ovarian cancer: In phase I studies evaluating telisotuzumab vedotin’s effects in 48 patients with advanced solid tumors (17 with non-small-cell lung cancer and 16 of them were c-Met positive NSCLC, 12 with nonsquamous, 5 with squamous, 4 with breast cancer, 9 with colon/rectal cancer, 2 with endometrial cancer, 4 with ovarian cancer and 12 with other solid cancers), the recommended dose of phase II was 2.7 mg/kg.